CELUW

Celularity Inc

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001752828
$0.004900 -43.68% $173.7K
High Impact Filing (8/10)
Vol
Market Cap$173.7K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$46.00
SEC Reports3
1 institutional holders with $46.00 total value (1,313 shares) as of 2025-Q3. Top holders: UBS.

Top Institutional Holders — 2025-Q3

#FundSharesValue% of TrackedLast Move
1UBS Group AG1,313$46.00100.0%

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 3, 2026
activist
Celularity Releases CEO Letter to Shareholders
<p align="left">FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-fo
May 29, 2026
activist
Celularity Receives Nasdaq Notice Regarding Form 10-Q
<p>FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellula
May 1, 2026
activist
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth <pre>Company advances focused strategy, stren
Apr 21, 2026
m_and_a
Celularity Announces Closing of Transaction with NexGel
<p>FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellul
Apr 17, 2026
activist
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
<p>FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellu
Mar 12, 2026
contract
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
<p align="left">FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerativ
Mar 10, 2026
other
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
<p>FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellula